Abeona Therapeutics (NASDAQ: ABEO) has recently received a number of price target changes and ratings updates:

  • 12/1/2017 – Abeona Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/23/2017 – Abeona Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. “
  • 11/22/2017 – Abeona Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. “
  • 11/22/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
  • 11/22/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $28.00 price target on the stock.
  • 11/20/2017 – Abeona Therapeutics was given a new $35.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock. They wrote, “Abeona reported 3Q17 with a net loss of $5.3M and ended the period with $56.5M in cash. The company also completed an equity financing in October raising $92M in cash. As of 10/31, Abeona reported $143M in cash on the balance sheet, sufficient runway for the next several years.””
  • 11/8/2017 – Abeona Therapeutics is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $26.00 price target on the stock.
  • 10/16/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $20.00.
  • 10/11/2017 – Abeona Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $21.00 to $34.00. They now have an “overweight” rating on the stock.
  • 10/10/2017 – Abeona Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $32.00 price target on the stock.
  • 10/9/2017 – Abeona Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $20.00.

Shares of Abeona Therapeutics Inc (NASDAQ ABEO) traded down $0.45 during trading on Thursday, reaching $14.80. The company’s stock had a trading volume of 625,200 shares, compared to its average volume of 627,739. Abeona Therapeutics Inc has a 1-year low of $4.05 and a 1-year high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. equities analysts predict that Abeona Therapeutics Inc will post -0.6 earnings per share for the current fiscal year.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.